Jame Abraham, MD, FACP
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New York Times, opened to the science section, and read aloud: “Cancer Researcher in South Africa Who Falsified Data Is Fired.”
The article detailed the case of Dr. Werner Bezwoda, whose fabricated data on high-dose chemotherapy with autologous stem cell transplantation for breast cancer had misled the global oncology community.
Just a year earlier, as a wide-eyed second-year NCI fellow, I had been sitting among thousands of oncologists at ASCO listening to Dr. Bezwoda present compelling dose-response curves and declare—with confidence—that high-dose chemotherapy with stem cell transplant was better. At the time, I was deeply interested in stem cell transplantation and was working with a principal investigator on stem cell transplant approaches for breast cancer. As a fellow, I admired Dr. Bezwoda. Many of us did.
In the late 1990s, therapeutic options for metastatic breast cancer were limited. Taxanes had only recently entered practice. Trastuzumab had not yet been approved. The prevailing philosophy was simple and seductive: push doses higher, rescue with stem cells, and try to keep patients alive through extraordinarily toxic therapy.
I vividly remember explaining the logic of dose intensity—drawing dose-response curves first described decades earlier—while speaking with women with metastatic breast cancer who came to the NIH searching for hope. We believed the science. We trusted the data.
That trust was misplaced.
Subsequent audits revealed that Dr. Bezwoda had clearly falsified results. Yet by then, high-dose chemotherapy and stem cell transplantation had already been widely adopted, particularly in the United States. Thousands of women underwent this treatment—enduring profound toxicity, suffering, and in some cases death—based on flawed evidence. Patient advocates, insurers, and hospitals had pushed for access and coverage, driven by desperation and belief in the promise of “more.”
As Colin Bundy, then Vice Chancellor of the University of the Witwatersrand, said, “For these women, there has been a rupture in the relationship of trust that should prevail in the medical profession.”
That rupture should still haunt us.
Twenty-five years later, sitting in the audience at the San Antonio Breast Cancer Symposium, I was struck by how far—and how unevenly—we have come. In the William L. McGuire Memorial Lecture, Dr. Armando Giuliano described the long and often lonely journey that led to the adoption of sentinel lymph node biopsy. He reminded us repeatedly that change is hard. His work showed the world that more surgery is not always better—that less can be just as effective, and often far kinder.
Later, patient advocate Ms. Beth Emery, JD, delivered a powerful challenge. After achieving a complete response to HER2-targeted therapy and chemotherapy, she nonetheless underwent a full axillary dissection—32 lymph nodes removed—followed by radiation. She asked investigators a question that has stayed with me:
“Are you demanding more evidence for de-escalation than you demand for adding a new therapy? And if so, why?”
That question echoes throughout modern oncology.
At San Antonio this year, de-escalation was not a sidebar—it was the theme. From screening to surgery, radiation, and systemic therapy, investigators asked whether more truly benefits patients. The WISDOM study challenged one-size-fits-all screening. Trials showed that preoperative breast MRI often does not improve outcomes. NSABP B-51 demonstrated no survival benefit to radiation in patients achieving a complete response. Multiple studies have shown that anthracyclines can be safely omitted for many patients. Trials have questioned the optimal duration of adjuvant trastuzumab and the role of dual HER2 blockade. Ongoing trials are questioning the necessity of adjuvant pembrolizumab after complete response in triple-negative disease, and whether all patients truly need adjuvant CDK4/6 inhibitors.
Interestingly, investigators from Tata Memorial Hospital, India have asked equally bold questions about appropriate dosing of immunotherapy—questions that directly affect patients worldwide.
Yet despite these efforts, de-escalation studies remain harder to fund, harder to publish, and harder to adopt. Pharmaceutical incentives naturally favor expansion, not refinement. But our obligation is not to maximize drug utilization, it is to identify who truly benefits, and who does not.
Looking back on my career in breast oncology, I am deeply grateful for the extraordinary advances that have transformed outcomes and quality of life. We are far removed from the era of high-dose chemotherapy and stem cell rescue. But progress does not absolve us from responsibility. Our patients are now asking us—not quietly, but clearly—to optimize care, not escalate it reflexively.
Breast cancer has always led the way in oncology. Once again, we must be willing to lead—this time by asking harder questions about less.
We cannot afford another rupture of trust.
Three Action Items for the Oncology Research Community
- Hold De-Escalation to the Same Evidentiary Standard as Escalation
If we demand phase III data to adopt a new therapy, we must demand—and act on—equally rigorous evidence when data support doing less. - Prioritize Patient-Centered Endpoints in Trial Design
Survival matters, but so do toxicity, function, financial burden, and quality of life. These outcomes must be primary, not secondary. - Leverage Genomics, AI, and Real-World Data to Identify Who Truly Benefits
Precision oncology should mean precision use—not simply more targeted drugs, but more targeted restraint when appropriate.
If we fail to learn these lessons, history will judge us not by what we added—but by what we refused to question.
DISCLOSURE: Dr. Abraham reported no conflicts of interest.
Dr. Abraham is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and Professor of Medicine at Lerner College of Medicine.
